Showing 1771-1780 of 3038 results for "".
- NORA Issues Response to Medical Groups' Joint Guidance of Vision Disorders Following a Concussionhttps://modernod.com/news/nora-response-to-medical-groups-joint-guidance-of-vision-disorders-following-a-concussion/2480978/Below is the response from the Neuro Optometric Rehabilitation Association (NORA) regarding the recent statement from various ophthalmic organizations i
- Bausch + Lomb and Novaliq Submit New Drug Application for Investigational NOV03 for Dry Eye Disease Associated with MGDhttps://modernod.com/news/bausch-lomb-and-novaliq-submission-new-drug-application-for-investigational-nov03-for-dry-eye-disease-associated-with-mgd/2480972/Bausch + Lomb and Novaliq announced the submission of a new drug application (NDA) at the end of June to FDA seeking approval for NOV03 (perfluorohexyloctane), an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease (DED) associated
- Glasgow Eye Department Now Using Ocular Simulation Training Through DRV Systemhttps://modernod.com/news/glasgow-eye-department-now-using-ocular-simulation-training-through-drv-system/2480954/Simulation exposure is now an essential component of the Royal College of Ophthalmologists’ Ophthalmic Specialist Training curriculum prior to real-life surgery, according to a news release from Vision Engineering Group, a maker of ergonomic stereo optical and digital instruments. &nbs
- Novartis Acquires Kedalion Therapeutics and its Ocular Delivery Platformhttps://modernod.com/news/novartis-acquires-kedalion-therapeutics-and-its-ocular-delivery-platform/2480952/Novartis announced that it has acquired Kedalion Therapeutics and its AcuStream technology, a device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.1,2 Terms of the deal were
- Efficacy of Notal Vision Home OCT Demonstrated by a Series of Scientific and Clinical Workhttps://modernod.com/news/efficacy-of-notal-vision-home-oct-demonstrated-by-a-series-of-scientific-and-clinical-work/2480942/Notal Vision reported that scientific and clinical publications and presentations demonstrate the feasibility and efficacy of their patient-operated, home-based optical coherence tomography (OCT) device. As part of a comprehensive remote monitoring service, which includes a monitoring center and
- Nicox Now Expects Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial in November 2022https://modernod.com/news/nicox-now-expects-topline-results-from-ncx-470-mont-blanc-phase-3-glaucoma-trial-in-november-2022/2480892/Nicox SA announced that it has closed screening for additional patients in its phase 3 Mont Blanc clinical trial of NCX 470 0.1% in patients with open-angle glaucoma or ocular hypertension. Therefore, the company now expects
- Novartis Receives FDA Approval of Beovu for the Treatment of Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-approval-of-beovu-for-the-treatment-of-diabetic-macular-edema/2480891/Novartis announced that the FDA has approved Beovu (brolucizumab-dbll) 6 mg for the treatment of diabetic macular edema (DME). Today’s approval represents the second FDA-approved indication for Beovu, which was first approved for the treatment of wet age-related macular degeneration in
- Belkin Vision's Automated, Non-Contact Glaucoma Laser Treatment Receives CE Markhttps://modernod.com/news/belkin-visions-eagle-receives-ce-mark-under-mdr/2480859/Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe. The CE Mark was granted under Medical Device Regulation (MDR) from its notified body DEKRA.
- Nova Eye Medical Reports Canaloplasty Data Demonstrating Sustained Reduction in IOP with iTrackhttps://modernod.com/news/nova-eye-medical-reports-canaloplasty-data-demonstrating-sustained-reduction-in-iop-with-itrack/2480849/Nova Eye Medical reported the recent publication of three investigator-led, retrospective case series which evaluated the long-term effectiveness of canaloplasty in patients with open-angle glaucoma (OAG) over 36- and 48-month periods, and in post-keratoplasty patients. Performed b
- Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03https://modernod.com/news/bausch-lomb-presents-data-from-second-pivotal-phase-3-trial-of-investigational-treatment-nov03-at-arvo/2480837/Bausch + Lomb and Novaliq announced that data from the second pivotal phase 3 trial (MOJAVE) of investigational treatment NOV03 (perfluorohexyloctane) were presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. NOV03 is being investigated as a first-in-c